Microwave Ablation for the Treatment of Non-Colorectal Cancer Liver Metastasis
Cancers · 23.06.2026 · 18 (13) · 2026
DOI: 10.3390/cancers18132026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.06.2026. Verfasst von Jacopo Lanari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, 35128 Padua, Italy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Non-colorectal cancer liver metastases (NCRLMs) represent a therapeutically challenging condition with poorly defined locoregional treatment options. This study evaluates the safety, oncological efficacy, and survival outcomes of microwave ablation (MWA) for NCRLMs in a large single-centre series.
Methods
Retrospective analysis of patients undergoing MWA for NCRLM between January 2010 and December 2024 at a high-volume hepatobiliary centre. Endpoints were safety, efficacy, textbook outcome (TO) achievement, and overall survival (OS).
Results
A total of 138 patients underwent 172 MWA procedures across eight primary tumour categories via a video-assisted (n = 110, 64%) or percutaneous (n = 62, 36%) approach. Major complications (Clavien–Dindo ≥ 3) occurred in 1.8% of procedures, with a median hospital stay of 2 days and a 90-day mortality of 1.7%. The median follow-up was 24.9 (10.3, 55.8) months. Complete response (CR) was achieved in 77% of procedures and TO in 54%, with incomplete response as the main driver of TO failure. The 5-year OS varied by histology, from 100% (GIST) and 80.0% (GEP-NET) to 44.7% (breast) and 0% (pancreatic adenocarcinoma). The video-assisted ablation was associated with superior OS compared to the percutaneous one (5-year OS 54.4% vs. 26.0%, p = 0.00025). In the multivariable analysis, the percutaneous approach (HR 2.44), ECOG PS ≥ 2 (HR 6.06) and a higher tumour burden score (HR 1.09) independently predicted worse OS, whereas the histological group was not independently associated with OS. Repeat MWA was the most frequent treatment for first hepatic recurrence, and 50% of patients reached no evidence of disease (NED) at last follow-up.
Conclusions
MWA is a safe and repeatable locoregional treatment for NCRLMs, with outcomes shaped by tumour biology, disease burden, patient fitness and procedural approach. The high rate of liver-dominant recurrence treated with repeat MWA, combined with a final NED rate of 50%, supports MWA as a platform for iterative locoregional disease control in selected patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, 35128 Padua, Italy.
- General Surgery and Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, Padua University Hospital, 35128 Padua, Italy.
- Department of Biology (DiBio), University of Padua, 35128 Padua, Italy.
ORCID-Profile: Jacopo Lanari, Sara Lazzari, Ilaria Billato, Clarissa De Nardi, Alessandro Furlanetto, Francesco Enrico D'Amico, Alessandro Vitale, Enrico Gringeri, Umberto Cillo
Zitieren
APA
Lanari, J., Lazzari, S., Billato, I., Naldini, C., De Nardi, C., Tamponi, G., Volpato, D., Furlanetto, A., D'Amico, F. E., Vitale, A., Gringeri, E., & Cillo, U. (2026). Microwave Ablation for the Treatment of Non-Colorectal Cancer Liver Metastasis. Cancers, 18(13), 2026. https://doi.org/10.3390/cancers18132026
Vancouver
Lanari J, Lazzari S, Billato I, Naldini C, De Nardi C, Tamponi G, et al. Microwave Ablation for the Treatment of Non-Colorectal Cancer Liver Metastasis. Cancers. 2026;18(13):2026. doi:10.3390/cancers18132026
BibTeX
@article{Lanari2026,
author = {Lanari, Jacopo and Lazzari, Sara and Billato, Ilaria and Naldini, Chiara and De Nardi, Clarissa and Tamponi, Giulia and Volpato, Davide and Furlanetto, Alessandro and D'Amico, Francesco Enrico and Vitale, Alessandro and Gringeri, Enrico and Cillo, Umberto},
title = {Microwave Ablation for the Treatment of Non-Colorectal Cancer Liver Metastasis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2026},
doi = {10.3390/cancers18132026}
}
EUVIMED